- Molecular NameRopivacaine
- SynonymRopivacaina [INN-Spanish]; Ropivacaina [Spanish]; Ropivacaine [INN]; Ropivacainum [INN-Latin]; S-Ropivacaine
- Weight274.408
- Drugbank_IDDB00296
- ACS_NO84057-95-4
- Show 2D model
- LogP (experiment)2.89
- LogP (predicted, AB/LogP v2.0)2.77
- pka8.16
- LogD (pH=7, predicted)1.91
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.15
- LogSw (predicted, AB/LogsW2.0)1.49
- Sw (mg/ml) (predicted, ACD/Labs)0.43
- No.of HBond Donors1
- No.of HBond Acceptors3
- No.of Rotatable Bonds4
- TPSA32.34
- StatusFDA approved
- AdministrationParenteral
- PharmacologyA local anaesthetic drug belonging to the amino amide group.
- Absorption_valueN/A
- Absorption (description)Bioavailability is 87%~98% following epidural administration.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding94.0
- Volume of distribution (VD)0.54~0.86 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmEliminated primarily by CYP1A2-dependent metabolism to 3-hydroxyropivacaine.
- Half life1.8 h
- ExcretionRenal 86%
- Urinary Excretion1
- Clerance5.5~7.1 ml/min/kg
- ToxicitySystemic exposure to excessive quantities of ropivacaine mainly result in central nervous system (CNS) and cardiovascular effects ?????? CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. CNS effects may include CNS excitation (nervousness, tingling around the mouth, tinnitus, tremor, dizziness, blurred vision, seizures) followed by depression (drowsiness, loss of consciousness, respiratory depression and apnea). Cardiovascular effects include hypotension, bradycardia, arrhythmias, and/or cardiac arrest ?????? some of which may be due to hypoxemia secondary to respiratory depression.
- LD50 (rat)N/A
- LD50 (mouse)N/A